Tumor-targeted paclitaxel delivery and enhanced penetration using TAT-decorated liposomes comprising redox-responsive poly(ethylene glycol)

Journal of Pharmaceutical Sciences

Volumn 104, Issue 3, 2015, Pages 1160-1173

  Fu, Han ^a   Shi, Kairong ^a   Hu, Guanlian ^a   Yang, Yuting ^a   Kuang, Qifang ^a   Lu, Libao ^a   Zhang, Li ^a   Chen, Wenfei ^a   Dong, Mingling ^a   Chen, Yantao ^a   He, Qin ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cancer; Cleavable PEG; Exogenous glutathione; Liposomes; Nanotechnology; Paclitaxel; Pegylation; Safety evaluation; Targeted drug delivery; TAT

Indexed keywords

ALANINE AMINOTRANSFERASE; CELL PENETRATING PEPTIDE; CREATINE KINASE; GLUTATHIONE; LIPOSOME; MACROGOL; PACLITAXEL; TRANSACTIVATOR PROTEIN; ANTINEOPLASTIC AGENT; LIPID; MACROGOL DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER INHIBITION; CREATINE KINASE BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TARGETING; DRUG UPTAKE; INTERNALIZATION; MELANOMA CELL LINE; NANOTECHNOLOGY; ANIMAL; C57BL MOUSE; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; MALE; MEDICINAL CHEMISTRY; MELANOMA, EXPERIMENTAL; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PHARMACEUTICS; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL-PENETRATING PEPTIDES; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; LIPIDS; LIPOSOMES; MALE; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; NANOTECHNOLOGY; OXIDATION-REDUCTION; PACLITAXEL; POLYETHYLENE GLYCOLS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84922763711     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24291     Document Type: Article

References (83)

1. Huh KM, Kang HC, Lee YJ, Bae YH. 2012. pH-sensitive polymers for drug delivery. Macromol Res 20 (3) : 224-233.
2. Koyamatsu Y, Hirano T, Kakizawa Y, Okano F, Takarada T, Maeda M. 2014. pH-responsive release of proteins from biocompatible and biodegradable reverse polymer micelles. J Control Release 173: 89-95.
3. Kim HJ, Miyata K, Nomoto T, Zheng M, Kim A, Liu X, Cabral H, Christie RJ, Nishiyama N, Kataoka K. 2014. siRNA delivery from triblock copolymer micelles with spatially-ordered compartments of PEG shell, siRNA-loaded intermediate layer, and hydrophobic core. Biomaterials 35 (15) : 4548-4556.
4. Gao H, Yang Z, Zhang S, Cao S, Pang Z, Yang X, Jiang X. 2013. Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth. J Control Release 172 (3) : 921-928.
5. Almeida JPM, Lin AY, Langsner RJ, Eckels P, Foster AE, Drezek RA. 2014. In vivo immune cell distribution of gold nanoparticles in naive and tumor bearing mice. Small 10 (4) : 812-819.
6. Chiang Y-T, Lo C-L. 2014. pH-Responsive polymer-liposomes for intracellular drug delivery and tumor extracellular matrix switched-on targeted cancer therapy. Biomaterials 35 (20) : 5414-5424.
7. López-Noriega A, Ruiz-Herńandez E, Quinlan E, Storm G, Hennink WE, O'Brien FJ. 2014. Thermally triggered release of a pro-osteogenic peptide from a functionalized collagen-based scaffold using thermosensitive liposomes. J Control Release187: 158-166.
8. Barenholz YC. 2012. Doxil R-The first FDA-Approved nano-drug: Lessons learned. J Control Release 160 (2) : 117-134.
9. Fassas A, Anagnostopoulos A. 2005. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma 46 (6) : 795-802.
10. Mei L, Fu L, Shi K, Zhang Q, Liu Y, Tang J, Gao H, Zhang Z, He Q. 2014. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG. Int J Pharm 468 (1) : 26-38.
11. Fang J, Nakamura H, Maeda H. 2011. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63 (3) : 136-151.
12. Gao W, Langer R, Farokhzad OC. 2010. Poly (ethylene glycol) with observable shedding. Angew Chemie Int Ed 49 (37) : 6567-6571.
13. Hatakeyama H, Akita H, Harashima H. 2011. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: A strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 63 (3) : 152-160.
14. Hatakeyama H, Akita H, Ito E, Hayashi Y, Oishi M, Nagasaki Y, Danev R, Nagayama K, Kaji N, Kikuchi H. 2011. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials 32 (18) : 4306-4316.
15. Zorko M, Langel U. 2005. Cell-penetrating peptides: Mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev 57 (4) : 529-545.
16. Ping Y, Hu Q, Tang G, Li J. 2013. FGFR-Targeted gene delivery mediated by supramolecular assembly between cyclodextrin-crosslinked PEI and redox-sensitive PEG. Biomaterials 34 (27) : 6482-6494.
17. Walker GF, Fella C, Pelisek J, Fahrmeir J, Boeckle S, Ogris M, Wagner E. 2005. Toward synthetic viruses: Endosomal pH-Triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. Mol Ther 11 (3) : 418-425.
18. McNeeley KM, Karathanasis E, Annapragada AV, Bellamkonda RV. 2009. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials 30 (23) : 3986-3995.
19. He Y, Nie Y, Xie L, Song H, Gu Z. 2014. p53 mediated apoptosis by reduction sensitive shielding ternary complexes based on disulfide linked PEI ternary complexes. Biomaterials 35 (5) : 1657-1666.
20. Kang C, Yu L, Cai G, Wang L, Jiang H. 2011. Well-defined succinylated chitosan-O-poly (oligo (ethylene glycol) methacrylate) for pH-reversible shielding of cationic nanocarriers. J Polym Sci [A] 49 (16) : 3595-3603.
21. Zhu C, Zheng M, Meng F, Mickler FM, Ruthardt N, Zhu X, Zhong Z. 2012. Reversibly shielded DNA polyplexes based on bioreducible PDMAEMA-SS-PEG-SS-PDMAEMA triblock copolymers mediate markedly enhanced nonviral gene transfection. Biomacromolecules 13 (3) : 769-778.
22. Mukhtar E, Adhami VM, Mukhtar H. 2014. Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther.
23. Li C, Qiu Y, Li X, Liu N, Yao Z. 2014. Biological evaluation of new antitumor taxoids: Alteration of substitution at the C-7 and C-10 of docetaxel. Bioorg Med Chem Lett 24 (3) : 855-859.
24. Gornstein E, Schwarz TL. 2014. The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions. Neuropharmacol 76: 175-183.
25. Veldhoen R, Banman S, Hemmerling D, Odsen R, Simmen T, Simmonds A, Underhill D, Goping I. 2013. The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis. Oncogene 32 (6) : 736-746.
26. Rohena CC, Mooberry SL. 2014. Recent progress with microtubule stabilizers: New compounds, binding modes and cellular activities. Nat Prod Rep331: 335-355.
27. Joshi M, Liu X, Belani CP. 2014. Taxanes, past, present, and future impact on non-small cell lung cancer. Anticancer Drugs 25: 571-583.
28. Liu Y-M, Chen H-L, Lee H-Y, Liou J-P. 2014. Tubulin inhibitors: A patent review. Expert Opin Ther Pat (0) : 69-88.
29. Singla AK, Garg A, Aggarwal D. 2002. Paclitaxel and its formulations. Int J Pharm 235 (1) : 179-192.
30. Kuai R, Yuan W, Li W, Qin Y, Tang J, Yuan M, Fu L, Ran R, Zhang Z, He Q. 2011. Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly (ethylene glycol) comodified liposomal delivery system via systemic administration. Mol Pharm 8 (6) : 2151-2161.
31. Kuai R, Yuan W, Qin Y, Chen H, Tang J, Yuan M, Zhang Z, He Q. 2010. Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes. Mol Pharm 7 (5) : 1816-1826.
32. Yuan W, Kuai R, Cai W, Ran R, Fu L, Yang Y, Qin Y, Liu Y, Tang J, Fu H. 2014. Increased delivery of doxorubicin into tumor cells using extracellularly activated TAT functionalized liposomes: In vitro and in vivo study. J Biomed Nanotechnol 10 (8) : 1563-1573.
33. Zhang Q, Tang J, Fu L, Ran R, Liu Y, Yuan M, He Q. 2013. A pH-responsive helical cell penetrating peptide-mediated liposomal delivery system. Biomaterials 34 (32) : 7980-7993.
34. Zhao B-X, Zhao Y, Huang Y, Luo L-M, Song P, Wang X, Chen S, Yu K-F, Zhang X, Zhang Q. 2012. The efficiency of tumor-specific pHresponsive peptide-modified polymeric micelles containing paclitaxel. Biomaterials 33 (8) : 2508-2520.
35. Liu Y, Ran R, Chen J, Kuang Q, Tang J, Mei L, Zhang Q, Gao H, Zhang Z, He Q. 2014. Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting. Biomaterials 35 (17) : 4835-4847.
36. Lee AL, Venkataraman S, Sirat S, Gao S, Hedrick JL, Yang YY. 2012. The use of cholesterol-containing biodegradable block copolymers to exploit hydrophobic interactions for the delivery of anticancer drugs. Biomaterials 33 (6) : 1921-1928.
37. Tang J, Fu H, Kuang Q, Zhang L, Zhang Q, Liu Y, Ran R, Gao H, Zhang Z, He Q. 2014. Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery. J Drug Target (0) : 1-14.
38. Bhattacharya C, Yu Z, Rishel MJ, Hecht SM. 2014. The carbamoylmannose moiety of bleomycin mediates selective tumor cell targeting. Biochemistry 53 (20) : 3264-3266.
39. Mo Y, Lim L-Y. 2005. Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA) -conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J Control Release 107 (1) : 30-42.
40. Tsai H, Tsai Sh, Deng Hw, Bor Fuh C. 2013. Assessment of cell viability using the chronoamperometric method based on screen-printed electrodes. Electroanalysis 25 (4) : 1005-1009.
41. Zhou J, Zhang X, Li M, Wu W, Sun X, Zhang L, Gong T. 2013. Novel lipid hybrid albumin nanoparticle greatly lowered toxicity of pirarubicin. Mol Pharm 10 (10) : 3832-3841.
42. Maruyama K. 2011. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev 63 (3) : 161-169.
43. Vivès E, Schmidt J, Pèlegrin A. 2008. Cell-penetrating and celltargeting peptides in drug delivery. Biochim Biophys Acta 1786 (2) : 126-138.
44. Yang T, Cui F-D, Choi M-K, Cho J-W, Chung S-J, Shim C-K, Kim D-D. 2007. Enhanced solubility and stability of PEGylated liposomal paclitaxel: In vitro and in vivo evaluation. Int J Pharm 338 (1) : 317-326.
45. Sriwongsitanont S, Ueno M. 2004. Effect of a PEG lipid (DSPEPEG2000) and freeze-Thawing process on phospholipid vesicle size and lamellarity. Colloid Polym Sci 282 (7) : 753-760.
46. Mehier-Humbert S, Bettinger T, Yan F, Guy RH. 2005. Plasma membrane poration induced by ultrasound exposure: Implication for drug delivery. J Control Release 104 (1) : 213-222.
47. Peer D. 2012. Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. Adv Drug Deliv Rev 64 (15) : 1738-1748.
48. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. 2010. Multicellular tumor spheroids: An underestimated tool is catching up again. J Biotechnol 148 (1) : 3-15.
49. Zhu L, Wang T, Perche F, Taigind A, Torchilin VP. 2013. Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. Proc Natl Acad Sci USA 110 (42) : 17047-17052.
50. Dombu CY, Kroubi M, Zibouche R, Matran R, Betbeder D. 2010. Characterization of endocytosis and exocytosis of cationic nanoparticles in airway epithelium cells. Nanotechnology 21 (35) : 355102.
51. Yu Z, Schmaltz RM, Bozeman TC, Paul R, Rishel MJ, Tsosie KS, Hecht SM. 2013. Selective tumor cell targeting by the disaccharide moiety of bleomycin. J Am Chem Soc 135 (8) : 2883-2886.
52. Hu Q, Gao X, Gu G, Kang T, Tu Y, Liu Z, Song Q, Yao L, Pang Z, Jiang X. 2013. Glioma therapy using tumor homing and penetrating peptide-functionalized PEG-PLA nanoparticles loaded with paclitaxel. Biomaterials 34 (22) : 5640-5650.
53. Gao H, Yang Z, Zhang S, Pang Z, Jiang X. 2014. Internalization and subcellular fate of aptamer and peptide dual-functioned nanoparticles. J Drug Target (0) : 1-10.
54. Gerecht S, Bettinger CJ, Zhang Z, Borenstein JT, Vunjak-Novakovic G, Langer R. 2007. The effect of actin disrupting agents on contact guidance of human embryonic stem cells. Biomaterials 28 (28) : 4068-4077.
55. Vaijayanthimala V, Tzeng Y-K, Chang H-C, Li C-L. 2009. The biocompatibility of fluorescent nanodiamonds and their mechanism of cellular uptake. Nanotechnology 20 (42) : 425103.
56. Eilers U, Klumperman J, Hauri H-P. 1989. Nocodazole, a microtubule-Active drug, interferes with apical protein delivery in cultured intestinal epithelial cells (Caco-2). J Cell Biol 108 (1) : 13-22.
57. Zhang X, Zhang Q, Peng Q, Zhou J, Liao L, Sun X, Zhang L, Gong T. 2014. Hepatitis B virus preS1-derived lipopeptide functionalized liposomes for targeting of hepatic cells. Biomaterials 35 (23) : 6130-6141.
58. Rejman J, Oberle V, Zuhorn I, Hoekstra D. 2004. Size-dependent internalization of particles via the pathways of clathrin-And caveolaemediated endocytosis. Biochem J 377: 159-169.
59. Gao H, Yang Z, Zhang S, Cao S, Shen S, Pang Z, Jiang X. 2013. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep 3.
60. Sun Q, Radosz M, Shen Y. 2012. Challenges in design of translational nanocarriers. J Control Release 164 (2) : 156-169.
61. Rejman J, Bragonzi A, Conese M. 2005. Role of clathrin-And caveolae-mediated endocytosis in gene transfer mediated by lipo-And polyplexes. Mol Ther 12 (3) : 468-474.
62. Huth US, Schubert R, Peschka-Süss R. 2006. Investigating the uptake and intracellular fate of pH-sensitive liposomes by flow cytometry and spectral bio-imaging. J Control Release 110 (3) : 490-504.
63. Zhao S, Dai W, He B,Wang J, He Z, Zhang X, Zhang Q. 2012. Monitoring the transport of polymeric micelles across MDCK cell monolayer and exploring related mechanisms. J Control Release 158 (3) : 413-423.
64. Eskandari MR, Fard JK, Hosseini M-J, Pourahmad J. 2012. Glutathione mediated reductive activation and mitochondrial dysfunction play key roles in lithium induced oxidative stress and cytotoxicity in liver. Biometals 25 (5) : 863-873.
65. Liu P, Yue C, Shi B, Gao G, Li M, Wang B, Ma Y, Cai L. 2013. Dextran based sensitive theranostic nanoparticles for near-infrared imaging and photothermal therapy in vitro. Chem Commun 49 (55) : 6143-6145.
66. Schmid I, Uittenbogaart CH, Keld B, Giorgi JV. 1994. A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. J Immunol Methods 170 (2) : 145-157.
67. Lee HJ, Pardridge WM. 2001. Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo. Bioconjug Chem 12 (6) : 995-999.
68. Li S-D, Huang L. 2010. Stealth nanoparticles: High density but sheddable PEG is a key for tumor targeting. J Control Release 145 (3) : 178.
69. Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Müller R. 2000. 'Stealth'corona-core nanoparticles surface modified by polyethylene glycol (PEG) : Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 18 (3) : 301-313.
70. Mosqueira VCF, Legrand P, Morgat J-L, Vert M, Mysiakine E, Gref R, Devissaguet J-P, Barratt G. 2001. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: Effects of PEG chain length and density. Pharm Res 18 (10) : 1411-1419.
71. Oumzil K, Khiati S, Grinstaff MW, Barthélémy P. 2011. Reductiontriggered delivery using nucleoside-lipid based carriers possessing a cleavable PEG coating. J Control Release 151 (2) : 123-130.
72. Zheng C, Zhang X, Sun L, Zhang Z, Li C. 2013. Biodegradable and redox-responsive chitosan/poly (L-Aspartic acid) submicron capsules for transmucosal delivery of proteins and peptides. J Mater Sci Mater Med 24 (4) : 931-939.
73. Li J, Huo M,Wang J, Zhou J, Mohammad JM, Zhang Y, Zhu Q,Waddad AY, Zhang Q. 2012. Redox-sensitive micelles self-Assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials 33 (7) : 2310-2320.
74. Aubry S, Burlina F, Dupont E, Delaroche D, Joliot A, Lavielle S, Chassaing G, Sagan S. 2009. Cell-surface thiols affect cell entry of disulfide-conjugated peptides. FASEB J 23 (9) : 2956-2967.
75. Cheng R, Feng F, Meng F, Deng C, Feijen J, Zhong Z. 2011. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J Control Release 152 (1) : 2-12.
76. Wang F, Zhang D, Zhang Q, Guo S, Zheng D, Hao L, Guo H, Li C. 2013. Tissue distribution and pharmacokinetics evaluation of DOMCFA micelles for intravenous delivery of PTX. J Drug Target 21 (2) : 137-145.
77. Landesman-Milo D, Peer D. 2012. Altering the immune response with lipid-based nanoparticles. J Control Release 161 (2) : 600-608.
78. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. 2008. The current state of serum biomarkers of hepatotoxicity. Toxicology 245 (3) : 194-205.
79. Admassie E, Engidawork E. 2011. Subchronic administration of Catha edulis F. (khat) extract is marked by elevation of cardiac biomarkers and subendocardial necrosis besides blood pressure alteration in rats. J Ethnopharmacol 136 (1) : 246-253.
80. Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, Muniappa N, Thudium D, Gerhold D, Holder DJ. 2010. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 28 (5) : 478-485.
81. Finco DR, Duncan JR. 1976. Evaluation of blood urea nitrogen and serum creatinine concentrations as indicators of renal dysfunction: A study of 111 cases and a review of related literature. Journal of American Veterinary Medical Association 168 (7) : 593-601.
82. Brigger I, Dubernet C, Couvreur P. 2002. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54 (5) : 631-651.
83. Allen TM, Hansen CB, de Menezes DEL. 1995. Pharmacokinetics of long-circulating liposomes. Adv Drug Deliv Rev 16 (2) : 267-284.